Thomas Olin was born in 1958. Executive Vice President Chief Scientific Officer and Head of R&D. Ph.D. in physiology and M.Sc. in biology, chemistry and geosciences. Olin has more than 25 years’ experience of both scientific and business management from biotechnology and pharmaceutical companies. He was part of the management group that led the budding off of Biovitrum from Pharmacia and was later part of the research and business development management at Biovitrum. Olin was responsible for the budding off of iNovacia from Biovitrum in 2006. He also has extensive experience of the licensing of pharmaceutical development projects. Other assignments include board member of Blasieholmen Investment Group Seed AB (publ). Appointed EVP CSO in 2023.
Board member since 2010 and former CEO of Kancera. Independent in relation to major shareholders.
Back